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Abstract We measured the levels of two L-amyloid (AL)-
sequestering proteins, apolipoprotein (Apo) E and transthyretin
(TTR), in ventricular human cerebrospinal fluid (CSF) of
Alzheimer’s disease (AD) patients and controls in relation to
brain histological findings. We also studied actin levels in CSF as
a marker of the biochemical role of these two proteins in the
cytoskeleton. We show that TTR levels in CSF were significantly
decreased in AD patients compared to controls and negatively
correlated with the senile plaque (SP) abundance. Moreover,
actin levels were positively linked to TTR levels and increased in
CSF samples of patients homozygous for the ApoE O4-allele. We
propose that TTR and ApoE4 may have competition in the
aggregation of AL and its deposition in the SP of AD brain. The
relationships between ApoE, TTR and actin could suggest a
metabolic implication of ApoE genetics and TTR levels in
cytoskeletal biochemistry which may be relevant to the
pathogenesis of AD.
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1. Introduction
Amyloid L (AL) is the major component of senile plaques
found in Alzheimer’s disease (AD) brain. AL also exists in a
soluble form in physiological £uids such as cerebrospinal £uid
(CSF) and plasma as well as in the conditioned media of
di¡erent cultured cell lines [1^3]. The mechanism by which
AL forms amyloid ¢brils is unknown. But emerging evidence
suggests that amyloid ¢bril formation is a critical step in the
pathogenesis of AD. CSF contains several factors that pro-
mote the solubility, transport and clearance of AL, mainly two
important proteins apolipoprotein E (ApoE) and transthyre-
trin (TTR).
ApoE has three common isoforms, E2, E3 and E4, encoded
by alleles O2, O3 and O4. The O4 allele is over-represented in
late-onset and sporadic AD; and its importance as a risk
factor for its development is now well established [4^6].
TTR is a homotetrameric protein each subunit of which has
a molecular weight of 15 kDa. Within the central nervous
system (CNS), TTR is the only known CSF protein synthe-
sized solely by the choroid plexus [7]. In CSF, TTR is the
principal thyroxine-binding protein [8], which suggests its pos-
sible implication in the active transport of thyroid hormone
from the blood stream into CSF [7]. Several lines of evidence
point to an active role of ApoE and TTR in ¢bril formation
in the brain. ApoE binds to L-peptide with high a⁄nity in
vitro [9], promotes AL ¢brillogenesis in vitro and induces
accumulation of the L-amyloid peptide in cultured vascular
smooth muscle [10^12], while TTR inhibits and prevents this
¢bril formation [12,13]. TTR in lumbar CSF was shown to be
correlated negatively with the degree of dementia in patients
with dementia of Alzheimer type [14]. Recently, we have
shown that ApoE levels increased in lumbar CSF in cases
with normal aging and more extensively with AD [15,16],
which has now been con¢rmed by others [17,18]. We also
reported that TTR levels increased with aging but decreased
with AD [19].
The aim of this work was to investigate how the two AL
amyloid-sequestering proteins ApoE and TTR may contribute
to the balance of amyloid formation in AD. We took into
account senile plaque (SP) abundance in the brain of the
same patients. We also veri¢ed the potential action of these
proteins in the cytoskeletal biochemistry by estimating, for the
¢rst time, actin levels in the CSF, the major component of the
micro¢lament. We studied these relationships because the in-
tracellular organization of actin ¢lament seemed to be regu-
lated by thyroxine, mainly transported by TTR in the CSF
[20]. We hypothesized that ApoE may also be involved in
actin regulation via its avidity for this protein [21]. We inves-
tigated the ApoE polymorphism e¡ects on these protein levels
in relation to brain histological ¢ndings.
2. Materials and methods
2.1. Patients and samples
This study was performed with 30 patients. Twenty patients were
con¢rmed by neuropathology examination at autopsy to have AD
without other complicating neurological or neuropathological features
(84.40 þ 1.79 years, ¢ve males and 15 females). Ten sex- and age-
matched controls (83.10 þ 3.49 years, three males and seven females)
were free of AD or other known neurological diseases (¢ve with
cerebrovascular disease without dementia, three multi-infarct demen-
tia, two with degenerative disc disease). The NINCDS-ADRDA work
group histological criteria for the diagnosis of ‘de¢nite Alzheimer’s
disease’ were used. Autopsies were performed within 24 h in the nurs-
ing home of the Hotel Dieu Hospital in Mont Saint-Martin (France).
Informed consent for brain autopsy had been obtained from the fam-
ilies of all patients. The CSF samples were obtained following opening
of the cranial cavity and withdrawal of the CSF syringe. Brain sec-
tions including middle temporal gyrus, middle frontal gyrus, and in-
ferior parietal lobule as well as hippocampus CA1 sections were ob-
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tained from all patients. Samples were frozen in liquid nitrogen and
stored until analyzed.
2.2. Histological analyses
Semiquantitative grading of senile plaques and neuro¢brillary tan-
gles in the tissue section were performed by immuno£uorescence using
monoclonal antibodies: antihuman L4 amyloid (Dako, Glostrup,
Denmark) and antihuman Tau1 (Boehringer Mannheim, Mannheim,
Germany) with FITC anti-mouse Ig (Institut Pasteur Productions,
Marnes, France) as a second-step reagent previously described [22].
For AD patients, immuno£uorescence revealed many SP with ho-
mogeneous frequency in the three neocortical regions. Control pa-
tients presented a few SP and threads. SP were classi¢ed as follows:
+, some; ++, moderate; and +++, abundant.
2.3. Protein measurements
The measurement of CSF total protein was made using a dye bind-
ing colorimetric method based on pyrogallol red-molybdate complex
(Biotrol, Paris, France) with a Cobas Mira analyzer (Roche Diagnos-
tics, Neuilly-sur-Seine, France). ApoE measurements in CSF were
performed by a sandwich enzyme-linked immunosorbent assay (ELI-
SA) as described elsewhere [16]. TTR was measured automatically
using an Array protein system (Beckman, Brea, CA, USA) as de-
scribed by the manufacturer with anti-TTR antibody (Beckman In-
struments, Galway, Ireland). The coe⁄cients of analytical variation
were 4.9% and 3.7% for inter-assay and intra-assay, respectively. Ac-
tin levels were estimated by quantitative study of samples separated
using high resolution, two-dimensional polyacrylamide gel electropho-
resis (2D-PAGE) performed with the ISO-DALT system [23]. The
staining of the 2D gels was performed with a neutral method using
silver nitrate [24] with sensitivity in the nanogram range. Alterna-
tively, proteins separated by 2D-PAGE were transferred to sheets of
nitrocellulose (SchleicherpSchuell, Inc., Dassel, Germany). Primary
antibodies to human TTR and actin were obtained from Sigma Bio-
chemicals. Alkaline phosphatase conjugated anti-goat and anti-mouse
was used as a secondary antibody. The 2D gels (18U16U0.15 cm)
were digitized using an Agfa 800 laser scanner with 1024 gray levels,
an optical density range of 0^3.2 and a spatial resolution of 250 Wm.
The image data were analyzed on a SUN workstation by the
HERMeS program [25]. Calibration and normalization for staining
and detection variation were done using the TTR content of samples
measured by nephelometry. To avoid variations which may be due
mainly to the silver staining of actin between samples, we studied
actin and TTR values from the same gel. In this way, the standard-
ization was essentially internal for each gel. Minor variations in load
volumes, for instance, would not alter the results. Values for CSF
samples in this study were represented by averages of two or more
replicates.
2.4. ApoE polymorphism study
First, PCR ampli¢cation of the sequences spanning the ApoE poly-
morphic sites was performed. Then, ApoE genotyping was performed
on DNA isolated from nucleated blood cells [26] and digested with
HhaI as described elsewhere [27]. When blood was not available, poly-
morphism was studied by phenotyping ApoE in CSF samples using
two-dimensional electrophoresis.
2.5. Statistical analysis
All data were analyzed with the BMDP statistical software (Los
Angeles, CA). The mean values were compared using the non-para-
metric Kruskal-Wallis test. We used the Spearman rank test to eval-
uate the relationship between ApoE, TTR and actin levels. P9 0.05
was considered signi¢cant.
3. Results
The analysis showed no signi¢cant di¡erence in the levels of
ApoE ( þ S.E.M.) between AD and control groups (1.05 þ 0.26
mg/l, n = 20 vs. 1.26 þ 0.31 mg/l, n = 10 respectively, P = 0.32)
(Fig. 1), but the mean CSF level of TTR in patients with AD
was signi¢cantly lower than that observed in controls
(22.21 þ 1.41 mg/l vs. 34.52 þ 4.12 mg/l respectively, P =
0.0094). Neither ApoE nor TTR levels were signi¢cantly cor-
related with those of albumin (not shown).
A semiquantitative estimation of senile plaques showed a
negative correlation (P = 0.035) between the SP abundance
and the mean levels of TTR in CSF of the same patients
(Fig. 2). The TTR levels were signi¢cantly higher in CSF of
patients with a few SP compared to those of patients with
abundant SP (P6 0.05). Correlation was lacking between
ApoE levels and SP abundance (P = 0.74). We showed a pos-
itive correlation between ApoE O4-allele frequency and the SP
abundance (P6 0.05, by M2 test). Age did not a¡ect the SP
abundance (P = 0.77). We also investigated the e¡ect of age on
ApoE and TTR levels in CSF. Neither ApoE nor TTR
changed signi¢cantly with age (data not shown).
In the CSF, analysis of TTR and acting using 2D-PAGE
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Fig. 1. Comparison of ApoE and TTR levels in CSF of AD pa-
tients and control patients. Each value is the mean of triple assays.
Bars represent the mean values.
Fig. 2. ApoE and TTR concentrations in CSF of AD patients as a
function of the SP abundance in the brain of the same patients. SP
ranged as follows: +, some (n = 7 patients); ++, moderate (n = 7);
+++, abundant (n = 7). The frequency of O4 in each group is shown.
*P6 0.05. Bars are S.E.M.
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(Fig. 3) showed two spots for actin with molecular masses
(MM) of about 43 kDa and di¡erent isoelectric points (pI)
of 5.24 and 5.28 and two or three spots for TTR (MM = 14
kDa and pI 5.04^5.55). The spots of actin and TTR were
identi¢ed either by immunostaining of the 2D blot or by
comparison with published maps. The correlation between
actin spot intensities and those of TTR showed a positive
relationship for all patients including AD and controls
(r = 0.54, P = 0.0088, n = 20, Fig. 4). The correlation remained
signi¢cant without the control patients (r = 0.60, P = 0.019,
n = 14). While that with the control group was not signi¢cant
(r = 0.46, P = 0.25, n = 7), no di¡erence was found in the actin
levels between AD and controls group (1.41 þ 0.22 mg/l
(n = 15) vs. 1.41 þ 0.28 mg/l (n = 7), P = 0.94).
When we took into account the e¡ect of the ApoE alleles
relative to actin levels variability (Fig. 5), we found an asso-
ciation with the dose of the O4 allele (P6 0.05). The levels
were: 1.01 þ 0.09 mg/l ( þ S.E.M.) for no O4 allele carriers
(n = 6); 1.09 þ 0.21 mg/l for one O4 allele carriers (n = 7) and
1.92 mg/l þ 0.32 for two O4 allele carriers (n = 9). Actin levels
were not statistically correlated with those of albumin
(r = 0.30, P = 0.20, n = 19) nor were they linked to the SP
abundance.
4. Discussion
This is the ¢rst report investigating transthyretin and actin
concentrations in ventricular human cerebrospinal £uid of
patients clinically and pathologically con¢rmed to have had
AD. A few biochemical studies of Alzheimer’s patients have
involved the analysis of CSF for transthyretin. A previous
study showed a negative association of TTR with degree of
dementia in lumbar CSF of patients with AD [14]. Now, we
report a negative correlation between TTR and one major
hallmark in the AD brain, the senile plaques. We also show
that TTR levels in AD CSF were signi¢cantly lower compared
to those of patients su¡ering from other neurological diseases
and we con¢rmed our recent ¢ndings in lumbar CSF [19]. We
note that ventricular TTR values in the present study are
higher than the lumbar ones [14,19] and this is due to the
fact that TTR, in contrast to most CSF proteins, decreases
from the ventricles to the lumbar space [7].
Meanwhile, we showed that the CSF mean levels of ApoE
in AD patients did not di¡er signi¢cantly from those in the
neurological patients. The results of studies regarding lumbar
CSF ApoE in AD are apparently controversial (see [15]).
However, the level of ApoE seems to be dependent on the
clinical state, genetics and other factors; but it is likely to
be linked to the death and damage caused by disease or in-
jury. Here, no speci¢c association of CSF ApoE levels with
the pathology of Alzheimer could be determined, probably
because the control group seemed to have had high levels of
ApoE [15]. Singly, variation of ApoE levels in CSF had no
evident implication in AD.
The precise mechanism by which TTR may be involved in
AD is unknown. Our ¢ndings provide strong support for a
role of TTR in Alzheimer’s pathogenesis by sequestering AL
and preventing ¢bril formation, as suggested by several in
vitro assays [10,11,27]. The decreased CSF mean levels of
TTR observed in patients with AD may re£ect a decreased
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Fig. 5. Analysis of actin levels in CSF of all patients (14 with AD
and seven with other neurological diseases) according to the O4 al-
lele dose of ApoE. Statistical di¡erences between allelic groups were
calculated using Kruskal-Wallis test, *P6 0.05. Bars are S.E.M.
Fig. 4. Relationship between actin and TTR levels in CSF of pa-
tients with AD (n = 14) and with other neurological diseases (n = 7).
The levels are re£ected by the total intensities of actin and TTR
proteins separated by 2D-PAGE, digitized using an Agfa 500 laser
scanner and analyzed by HERMeS image analysis software. Spear-
man correlation coe⁄cient with all patients was r = 0.54, P = 0.0088.
The closed circles and the open squares correspond to AD and the
neurological diseases groups, with r = 0.60 (P = 0.019, n = 14) and
r = 0.46 (n = 7, P = 0.25), respectively.
Fig. 3. High resolution 2D-PAGE of silver-stained human CSF pro-
teins. Actin (pI : 5.24 and 5.28; MW: 43 kDa) and TTR spots (pI :
5.55 and 5.3; MW: 14 kDa) are indicated by the arrows.
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synthesis of this protein by the choroid plexus in the brain.
This is probably linked to the alterations in the structure of
the latter which we have recently found with aging and more
extensively with Alzheimer’s pathology [28]. However, we can-
not exclude an accelerated uptake of TTR from CSF via a
speci¢c receptor [29].
Another side of TTR implication poorly investigated in AD
may be at the levels of hormonal regulation and delivery. In
CSF, where TTR is the principal thyroxine binding protein,
the TTR-thyroxine complex seems to have a distributive func-
tion, assuring availability of thyroxine to cells through the
CSF circulation [30]. To better estimate this role, we studied
the actin levels as potential target of the hormonal distributive
action of TTR in the brain cytoskeleton. Thyroxine was
shown to regulate the actin polymerization in the micro¢la-
ment structure in astrocytes [20], e.g. the equilibrium between
G-actin (soluble) and F-actin (insoluble) and consequently,
the soluble form levels of actin in the extracellular £uid.
The positive correlation that we reported here between actin
and TTR levels in the CSF and the decrease of TTR levels
with AD may have such biological relevance. Further inves-
tigations are needed to con¢rm this hypothesis.
The high levels of actin in CSF obtained with the O4 allele
carrier patients may be due to the extensive damage in the
brain cells of these patients in relation to the O4 allele [31].
Interestingly, ApoE seems to have allele-dependent a⁄nity for
some cytoskeleton components such as tau, MAP2 and actin
[21], probably controlling the stability of the cytoskeleton and
the normal neuronal function. The O4 allele is thought to have
a negative contribution to this process. The correlation re-
ported here between actin in CSF and the O4 allele may re£ect
one cytoskeletal abnormality characterized by a destabiliza-
tion of the actin ¢laments, a process that might be enhanced
by the ApoE4 isoform. Alternatively, TTR and ApoE4 could
have di¡erent e¡ects on actin regulation, indirectly by inter-
acting with APP which was shown to be associated with the
cytoskeleton [32] and seems to be directly implicated in the
actin expression [33].
As a whole, TTR levels in CSF appear to be speci¢cally
decreased in AD and negatively correlated with SP abun-
dance. These results reinforce the designation of TTR as a
potential factor implicated in ¢brillogenesis prevention and
point to the utility of TTR determination in CSF of AD.
Actin in the CSF may serve as a marker of the brain cyto-
skeletal integrity and with a lesser extent of particular TTR
and/or ApoE functions in the brain.
Acknowledgements: We wish to thank the patients’ families for their
generous cooperation and understanding. We thank W. Ru¡ for im-
proving the language of this paper and M. Starck and M.P. Recou-
vreur for their technical assistance. This work was partially supported
by the ‘Alzheimer 54’ Institution and the Region de La Lorraine.
References
[1] Smith, C. and Anderton, B.H. (1994) Neuropathol. Appl. Neuro-
biol. 20, 322^338.
[2] Haass, C., Schlossmacher, M.G., Hung, A., Vigo-Pelfrey, C.,
Mellon, A., Ostaszewski, B., Lieberburg, I., Koo, E.H., Shenk,
D., Teplow, D.B. and Selkoe, D.J. (1992) Nature 359, 322^325.
[3] Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Da-
vis, D., Shinha, S., Schlossmacher, M., Whaley, J., Swindlehurst,
C., McCormack, R., Wolfert, R., Selkoe, D., Lieberburg, I. and
Schenk, D. (1992) Nature 359, 325^327.
[4] Strittmatter, W.J., Sauders, A.M., Schmechel, D., Pecicak-Vance,
M., Enghild, J., Salvesen, G.S. and Roses, A.D. (1993) Proc.
Natl. Acad. Sci. USA 9, 1977^1981.
[5] Kuusisto, J., Koivisto, K., Mykkaºnen, L., Helkala, E.L., Vanha-
nen, M., Haºnninen, T., Pyoºraºlaº, K., Kesaºniemi, Y.A., Riekkinen,
P. and Vanhanen, M. (1994) Br. Med. J. 309, 636^638.
[6] Siest, G., Pillot, T., ReŁgis-Bailly, A., Leninger-Muller, B., Stein-
metz, J., Galteau, M.-M. and Visvikis, S. (1995) Clin. Chem. 41,
1068^1086.
[7] Herbert, J., Wilcox, J.N., Pham, K.-T.C., Fremeau Jr., R.T.,
Zeviani, M., Dwork, A., Soprano, D.R., Makover, A., Good-
man, D.S., Zimmerman, E.A., Roberts, J.L. and Schon, E.A.
(1986) Neurology 36, 900^911.
[8] Hagen, G.A. and Elliott, W.J. (1973) J. Clin. Endocrinol. Metab.
37, 415^422.
[9] Strittmatter, W.J., Weisgraber, K.H., Huang, D.Y., Dong,
L.-M., Salvesen, G.S., Pecicak-Vance, M., Schmechel, D.,
Sauders, A.M., Goldgaber, D. and Roses, A.D. (1993) Proc.
Natl. Acad. Sci. USA 90, 8098^8102.
[10] Ma, J., Yee, A., Brewer, H.B., Das, S. and Potter, H. (1994)
Nature 372, 92^94.
[11] Wisniewski, T., Castano, E.M., Golabek, A., Vogel, T. and Fran-
gione, B. (1994) Am. J. Pathol. 145, 1030^1035.
[12] Mazur-Koleka, B., Frackowiak, J. and Wisniewski, H.M. (1995)
Brain Res. 698, 217^222.
[13] Schwarzman, A.L., Gregori, L., Vitek, M.P., Lyubski, S., Stritt-
matter, W.J., Enghilde, J.J., Bhasin, R., Silverman, J., Weisgra-
ber, K.H., Coyle, P.K., Zagorski, M.G., Talafous, J., Eisenberg,
M., Sauders, A.M., Roses, A.D. and Goladgaber, D. (1994)
Proc. Natl. Acad. Sci. USA 91, 8368^8372.
[14] Riisoen, H. (1988) Acta Neurol. Scand. 78, 455^459.
[15] Merched, A., Blain, H., Visvikis, S., Herbeth, B., Jeandel, C. and
Siest, G. (1997) J. Neurol. Sci. 145, 33^39.
[16] Blain, H., Merched, A., Visvikis, S., Siest, G. and Jeandel, C.
(1997) J. Am. Geriatr. Soc. 45, 1536.
[17] Lindh, M., Blomberg, M., Jensen, M., Basun, H., Lannfelt, L.,
Engvall, B., Scharnagel, H., Marz, W., Wahlund, L.O. and Cow-
burn, R.F. (1997) Neurosci. Lett. 229, 85^88.
[18] Song, H., Saito, K., Seishima, M., Noma, A., Urakami, K. and
Nakashima, K. (1997) Neurosci. Lett. 231, 175^178.
[19] Serot, J.M., Chrismann, D., Dubost, T. and Couturier, M. (1997)
J. Neurol. Neurosurg. Psychiatry 63, 506^508.
[20] Siegrist-Kraiser, C.A., Juge-Aubray, C., Tranter, M.P., Eken-
barger, D.M. and Leonard, J.L. (1990) J. Biol. Chem. 265,
5296^5302.
[21] Fleming, L.H., Weisgraber, K.H., Strittmatter, W.J., Troncosco,
J.C. and Johson, G.N.W. (1996) Exp. Neurol. 138, 252^260.
[22] Serot, J.M., BeŁneŁ, M.C. and Faure, G.C. (1994) Hum. Pathol.
25, 1185^1190.
[23] Visvikis, S., Steinmeitz, J., Cuvelier, I., Galteau, M.M. and Siest,
G. (1986) in: Recent Progress in Two-Dimensional Electropho-
resis (Galteau, M.M. and Siest, G., Eds.), pp. 159^165, Presses
Universitaires, Nancy.
[24] Rabillou, T. (1992) Electrophoresis 13, 429^439.
[25] Tarroux, P. and Vincens, P. (1987) Electrophoresis 8, 173^199.
[26] Miller, S.A., Dykes, D.D. and Polesky, S. (1988) Nucleic Acids
Res. 16, 12^15.
[27] Hixson, J.E. and Vernier, D.T. (1990) J. Lipid Res. 31, 545^548.
[28] Serot, J.M., BeŁneŁ, M.C., Foliguet, B. and Faure, G.C. (1997)
Ann. NY Acad. Sci. 826, 507^509.
[29] Divino, C.M. and Schussler, G.C. (1990) J. Biol. Chem. 265,
1425^1429.
[30] Mendel, C.M., Weisiger, R.A., Jones, A.L. and Cavalieri, R.R.
(1987) Endocrinology 120, 1742^1749.
[31] Corder, E.H., Sauders, A.M., Strittmatter, W.J., Schmechel,
D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L.
and Pericak-Vance, M.A. (1993) Science 261, 921^923.
[32] Refolo, L., Wittenberg, I.S., Freidrich, V.L. and Robakis, N.K.
(1991) J. Neurosci. 11, 3888^3897.
[33] Ramakrishna, N., Smedman, M., Ramakrishna, V. and Gillam,
B. (1997) Biochem. Biophys. Res. Commun. 231, 615^618.
FEBS 20001 27-3-98
A. Merched et al./FEBS Letters 425 (1998) 225^228228
